ACG Metals Limited (LON:ACG)

Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Net Income	-10.46	-13.58
Depreciation & Amortization	5.77	-
Stock-Based Compensation	0.84	-
Other Operating Activities	14.26	2.62
Change in Accounts Receivable	-5.59	-0.08
Change in Inventory	2.23	-
Change in Accounts Payable	16.33	-0.39
Change in Unearned Revenue	-0.02	-
Change in Income Taxes	-6.41	-
Change in Other Net Operating Assets	0.04	-
Operating Cash Flow	17	-11.43
Capital Expenditures	-2.01	-
Cash Acquisitions	-64.68	-
Sale (Purchase) of Intangibles	0.12	-
Other Investing Activities	0.88	3.5
Investing Cash Flow	-65.68	3.5
Short-Term Debt Issued	32.55	-
Total Debt Issued	32.55	8.07
Short-Term Debt Repaid	-13.6	-
Total Debt Repaid	-13.6	-
Net Debt Issued (Repaid)	18.95	8.07
Issuance of Common Stock	36.98	66.49
Repurchase of Common Stock	-0.59	-70.49
Other Financing Activities	-	2.25
Financing Cash Flow	55.34	6.32
Foreign Exchange Rate Adjustments	-0.08	-
Miscellaneous Cash Flow Adjustments	-	-0
Net Cash Flow	6.57	-1.62
Free Cash Flow	14.99	-11.43
Free Cash Flow Margin	32.50%	-
Free Cash Flow Per Share	1.81	-6.36
Cash Income Tax Paid	6.41	-
Levered Free Cash Flow	33.59	-
Unlevered Free Cash Flow	35.52	-
Change in Net Working Capital	-28.41	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.